Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px
Document › Details

AdBio Partners SAS. (2/23/23). "Press Release: AdBio Partners Appoints Geoffroy de Ribains as Managing Partner". Paris.

Organisations Organisation AdBio Partners SAS (AFB)
  Group AdBio Partners (Group)
  Organisation 2 Gamut Therapeutics SAS
  Group SparingVision SAS
Products Product venture capital
  Product 2 LIFE SCIENCES
Persons Person de Ribains, Geoffroy (AdBio Partners 202302– promoted to Managing Parnter joined AFB 2009 before Step Pharma + Biomunex)
  Person 2 Huriez, Alain (Advent France Biotechnology 201704 Managing Partner before Advent Life Sciences + TcLand + Neovacs)
     


AdBio partners, a venture capital company specialized in seed investments in life sciences startups, today announces that it has appointed Geoffroy de Ribains as Managing Partner.

In his new role, Geoffroy joins the management team of AdBio partners, which currently manages two funds and has 22 companies in its portfolio.

“Geoffroy’s promotion to the position of Managing Partner comes off the back of four years of close and fruitful collaboration with AdBio partners. We are delighted that he is now joining the management team. Geoffroy has a recognized expertise in the creation and development of start-ups as spin-offs from academic research, and in portfolio management, as he has already demonstrated through his involvement with several companies in our portfolio. This appointment is perfectly in line with our growth dynamic, which will actively continue this year,” said Alain Huriez, co-founder and chairman of AdBio partners.

Soon after joining AdBio partners in 2019 as an Entrepreneur in Residence, Geoffroy co-founded and managed Gamut Therapeutics, a gene therapy company specialized in the field of ophthalmology. This start-up was acquired in 2021 by SparingVision, a leading French company in ocular gene therapy.

In 2020, Geoffroy joined AdBio partners’ investment team as Operating Partner, before being promoted to Partner in 2021. He has since contributed to the management of the AFBSFI fund portfolio and the development of the AFBFII fund portfolio.

Before joining AdBio partners, Geoffroy was CEO of the French biotechnology start-up Step Pharma, which he co-founded and directed from target discovery through to preclinical candidate stage. To date, this company has raised €52 million ($55M) in equity; its product, STP938, is currently in phase I/II clinical trials for the treatment of T-cell lymphomas. Geoffroy also co-founded Biomunex Pharmaceuticals. Prior to that, he spent 12 years working as a venture capital investor for Andera Partners and Atlas Venture, which saw him directly involved in 20 investments and six M&A transactions, as well as serving on the board of directors of eight companies. Geoffroy
de Ribains holds a European master’s degree in genetics from Paris Diderot University – Paris 7.


About AdBio partners

AdBio partners (previously Advent France Biotechnology) is an AMF-regulated (the French financial market authority) company that invests in a range of sectors within life sciences - specifically in therapeutics-oriented projects.

Its unique strategy combines early-stage investments in promising enterprises and strong entrepreneurial support to strengthen the company’s growth.

Created in 2016, AdBio partners has made 22 European investments in France, Belgium, Spain and Ireland - with two funds AFB Seed Fund I* and AFB FII.

AdBio partners has developed strong relationships within the European innovation ecosystem; as a result, it has attracted international VC syndicates to its portfolio companies.

The operational team includes investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific, medical and operational expertise.

www.adbio.partners


*AFB Seed Fund I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.


Press and analyst contacts

Andrew Lloyd & Associates
Celine Gonzalez / Saffiyah Khalique
UK: +44 1273 952 481
US: +1 203 724 595
@ALA_Group

   
Record changed: 2024-03-30

Advertisement

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for AdBio Partners (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px




» top